Two New Published Clinical Papers on Vycor Medical’s VBAS Point to New Procedures, Broader Market Potential, and Improved Safety

BOCA RATON, FL / ACCESSWIRE / March 26, 2015 / Vycor Medical, Inc. (“Vycor”) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that two new important peer-reviewed studies have been published utilizing its ViewSite Brain Access System (“VBAS”). The studies appear in the March editions of World Neurosurgery and Neurological Research, and follow on from the study published earlier this month in the prestigious Journal of Neurosurgery which also featured VBAS on its front cover.

Management has consistently stated that it is this type of high quality clinical data that continues to evidence the clinical superiority of VBAS, which in turn drives its adoption and accelerates the hospital approval process, which in turn drives revenues. There have now been seven peer-reviewed studies published on VBAS and two white papers evidencing its clinical advantages which will over time ensure that the product becomes the standard of care for brain retraction and access. For a link to the clinical data, see VBAS Clinical Studies.

The World Neurosurgery article entitled “A Percutaneous Transtubular Middle Fossa Approach for Intracanalicular Tumors” was authored by Antonio Bernardo et al. of the Department of Neurological Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York. The study concluded: “All 10 approaches were successfully completed through the tubular retractor [VBAS] with minimal retraction of the temporal lobe. Excellent visualization of the structures within the internal auditory canal was achieved with both the microscope and 3D endoscope…” 

The Neuroogical Research article entitled “Rigid endoscopic resection of deep-seated or intraventricular brain tumors” was authored by Yukinori Akiyama et al. of the Dept of Neurosurgery, Sapporo Medical University, School of Medicine, Hokkaido Japan. This was an 18 patient study that concluded: “Strong retraction may cause significant brain and vascular damage; tubular retractors can help minimize retraction injury. The rigid endoscopic technique using a thick tubular sheath [VBAS] provides an alternative medial approach that improves visualization and increases working space. We believe that this technique [rigid endoscope resection through a sheath] is a safer, more reliable, and less invasive method for the treatment of deep-seated brain tumors”.

World Neurosurgery is the official journal of the World Federation of Neurosurgical Societies (WFNS), a professional, scientific, non-governmental organization representing some 30,000 neurosurgeons worldwide. World Neurosurgery is recognized as not only conveying high-level peer reviewed clinical and laboratory neuroscience, but also to address issues of educational relevance. Neurological Research is an international, peer-reviewed journal for reporting both basic and clinical research in the fields of neurosurgery, neurology, neuroengineering and neurosciences. It provides a medium for those who recognize the wider implications of their work and who wish to be informed of the relevant experience of others in related and more distant fields.

About Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB: VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical’s ViewSite(TM) Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU – Class III), Korea and Japan and is seeking or has partial regulatory approvals in Brazil, India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical’s VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company’s proprietary Visual Restoration Therapy(R) (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any Physician. VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed a therapy called NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to VRT(TM). The two therapies address different visual disabilities each of which results from neurologically-induced vision loss – a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

Vycor Medical, Inc Contacts:

6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

SOURCE: Vycor Medical, Inc.

ReleaseID: 427249